The Federal State Unitary Enterprise “State Scientific Research Institute of Highly Pure Biopreparations” FMBA decided to return to the market the original drug Rexod® (INN: superoxide dismutase), which was developed and produced by the Institute.
The drug is available in a new dosage form – solution for injection.
Superoxide dismutase is an endogenous acceptor of free oxygen radicals. Because of their excessive accumulation in the cells, pathological processes develop, and the current removes free radicals and prevents the formation of new hydroxyl and singlet radicals that are dangerous for the body.
An important pharmacological action of the drug is prevention of accumulation in the focus of inflammation of neutrophils, causing the destruction of nearby tissues.
The developers have conducted a number of studies and plan to expand the scope of the drug for the treatment of complications of radiation therapy of cancer, as well as in lateral amniotrophic sclerosis and in resuscitation practice.
Currently, the only indicator is the comprehensive prevention of the development of intraoperative complications in endoprosthetics of large joints using bone cement.